- Home
- UEC vs DNLI Comparison
UEC vs DNLI Comparison
Compare UEC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UEC
- DNLI
- Stock Information
- Founded
- UEC 2003
- DNLI 2013
- Country
- UEC United States
- DNLI United States
- Employees
- UEC N/A
- DNLI N/A
- Industry
- UEC Other Metals and Minerals
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UEC Basic Materials
- DNLI Health Care
- Exchange
- UEC Nasdaq
- DNLI Nasdaq
- Market Cap
- UEC 3.0B
- DNLI 3.1B
- IPO Year
- UEC N/A
- DNLI 2017
- Fundamental
- Price
- UEC $5.68
- DNLI $20.73
- Analyst Decision
- UEC Strong Buy
- DNLI Strong Buy
- Analyst Count
- UEC 2
- DNLI 13
- Target Price
- UEC $10.63
- DNLI $37.91
- AVG Volume (30 Days)
- UEC 6.7M
- DNLI 814.8K
- Earning Date
- UEC 03-10-2025
- DNLI 03-04-2025
- Dividend Yield
- UEC N/A
- DNLI N/A
- EPS Growth
- UEC N/A
- DNLI N/A
- EPS
- UEC N/A
- DNLI N/A
- Revenue
- UEC $17,203,000.00
- DNLI N/A
- Revenue This Year
- UEC $60,962.50
- DNLI N/A
- Revenue Next Year
- UEC $34.61
- DNLI $289.18
- P/E Ratio
- UEC N/A
- DNLI N/A
- Revenue Growth
- UEC N/A
- DNLI 204.74
- 52 Week Low
- UEC $4.06
- DNLI $14.56
- 52 Week High
- UEC $8.93
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- UEC 28.88
- DNLI 42.56
- Support Level
- UEC $5.84
- DNLI $21.33
- Resistance Level
- UEC $7.20
- DNLI $22.81
- Average True Range (ATR)
- UEC 0.34
- DNLI 1.27
- MACD
- UEC -0.12
- DNLI -0.10
- Stochastic Oscillator
- UEC 3.79
- DNLI 15.83
About UEC Uranium Energy Corp.
Uranium Energy Corp is engaged in uranium mining and related activities. The company is working towards fueling the demand for carbon-free nuclear energy, a key solution to climate change, and energy source for the low-carbon future. The company is advancing its next generation of low-cost, environmentally friendly, in-situ recovery (ISR) mining uranium projects. The company has two extraction-ready ISR hub and spoke platforms in South Texas and Wyoming. UEC also has seven U.S. ISR uranium projects with all of their permits in place, with additional diversified holdings of uranium assets across the U.S., Canada and Paraguay.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.